한국어
English
日本語
中文(简体)NJmo Injection (Sutimlimab)
1100mg
Injections · Prescription medication
Recordati Pharma Korea Co., Ltd.
Sutimlimab is an immunomodulatory antibody component used to treat autoimmune hemolytic anemia.
MFDS ingredient code M283921
Sutimlimab is a monoclonal antibody that targets specific immune proteins. It is used to regulate abnormally activated immune responses in autoimmune diseases. It is primarily utilized for the treatment of autoimmune hemolytic anemia.
Sutimlimab works by blocking specific proteins in the complement system to prevent the destruction of red blood cells. This helps to alleviate anemia symptoms by preventing the immune system from attacking its own red blood cells.
Approved uses differ by product. Check each product's information for its actual use.
Sutimlimab is the first therapy that selectively inhibits the classical pathway of the complement system, and unlike conventional immunosuppressants, it has a clear target and relatively fewer side effects.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.